Editorials The trouble with dabigatran BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4681 (Published 23 July 2014) Cite this as: BMJ 2014;349:g4681 Article Related content Metrics Responses Peer review Related articles Feature Concerns over data in key dabigatran trial Published: 23 July 2014; BMJ 349 doi:10.1136/bmj.g4747 Feature Dabigatran: how the drug company withheld important analyses Published: 23 July 2014; BMJ 349 doi:10.1136/bmj.g4670 Analysis Dabigatran, bleeding, and the regulators Published: 23 July 2014; BMJ 349 doi:10.1136/bmj.g4517 Editor's Choice Dabigatran and statins: faith, hype, and transparency Published: 24 July 2014; BMJ 349 doi:10.1136/bmj.g4793 News Report questions FDA approval of controversial anticoagulant Published: 19 October 2015; BMJ 351 doi:10.1136/bmj.h5557 See more Stroke: Take test for genetic variant to ensure clopidogrel works for prevention, says NICE BMJ May 19, 2023, 381 p1146; DOI: https://doi.org/10.1136/bmj.p1146 David Oliver: What the plan for social care omitted BMJ September 10, 2021, 374 n2227; DOI: https://doi.org/10.1136/bmj.n2227 Stroke: “striking reductions” are seen in number of people with symptoms seeking help BMJ April 06, 2020, 369 m1406; DOI: https://doi.org/10.1136/bmj.m1406 NICE recommends implantable monitor to identify atrial fibrillation after stroke BMJ January 14, 2020, 368 m133; DOI: https://doi.org/10.1136/bmj.m133 Thrombectomy can be considered up to 24 hours after onset of stroke, says NICE BMJ November 23, 2018, 363 k4995; DOI: https://doi.org/10.1136/bmj.k4995 Cited by... Bleeding complications of targeted oral anticoagulants: what is the risk?Abstract Fulltext PDF Novel oral anticoagulants: too good to be true?Abstract Fulltext PDF Boehringer Ingelheim withheld safety analyses on new anticoagulant, The BMJ investigation findsAbstract Fulltext PDF
